Listenly

What approach does Judy Health take to biosimilar formulary strategy compared to traditional PBMs?

Answered at 16:00 in Episode 66 - Designing the Future PBM Model with Judi Health · HR Benecast

— questions searchable right now

What approach does Judy Health take to biosimilar formulary strategy compared to traditional PBMs?

Judy Health uses a biosimilar-first approach across formulary offerings with broad options still covering reference products for unions and organizations requiring broader access. When reference products are removed from formulary, Judy steers toward low-WAC biosimilars, such as low-cost versions of Humira and Stellara. Because Judy does not profit from the medication itself as a fee-for-service organization, it can prioritize steering to the lowest-cost medication without sacrificing clinical outcomes.

Nick Van Hook on HR BenecastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Judy Health uses a biosimilar-first approach across formulary offerings with broad options still covering reference products for unions and organizations requiring broader access.

Nick Van Hook, Senior Vice President of National Business Development at Judy Health · Episode 66 - Designing the Future PBM Model with Judi Health · HR Benecast · answer at 16:00

Key takeaways

  • Judy Health uses a biosimilar-first approach across formulary offerings with broad options still covering reference products for unions and organizations requiring broader access.

Quote to remember

“We wanted to get back to what the core roots of PBM was when they started, and that was be the best administrator, a fee for service organization that had arm's length relationships throughout the supply chain.”

— Nick Van Hook

The full answer · about 2 min

Judy Health uses a biosimilar-first approach across formulary offerings with broad options still covering reference products for unions and organizations requiring broader access. When reference products are removed from formulary, Judy steers toward low-WAC biosimilars, such as low-cost versions of Humira and Stellara. Because Judy does not profit from the medication itself as a fee-for-service organization, it can prioritize steering to the lowest-cost medication without sacrificing clinical outcomes.

Key facts

  • Over 15 years in the pharmacy benefit space (Nick Van Hook's career history)
  • Over 7 years with Judy Health (Nick Van Hook's tenure)
  • 9 years since Judy Health's inception
  • 12 or 13 states with minimum reimbursement requirements based on NADAC plus dispensing fee
  • Specialty spend represents over half of total pharmacy spend for many clients

People, companies and topics mentioned

Judy HealthStarkRxJudyRxHR BenecastNADAC (National Average Drug Acquisition Cost)MedcoExpress ScriptsTraveris

More answers from this episode

 ·  All answers from HR Benecast →
—
—
0:00
0:00